Navigation Links
Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
Date:9/12/2013

CAMBRIDGE, Mass., Sept. 12, 2013 /PRNewswire/ -- Genocea Biosciences Inc., a clinical-stage biopharmaceutical company developing T cell vaccines to prevent and treat infectious diseases, reported today positive results from a planned analysis of a Phase 1/2a clinical study of its lead candidate, GEN-003, a first-in-class investigational protein subunit vaccine to treat patients with recurrent outbreaks of genital herpes simplex virus type 2 (HSV-2) infection. The data, presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013), show that patients who received three doses of GEN-003 had reductions in the frequency of viral shedding of up to 51 percent (p<0.001). By contrast, those who received a placebo had no decline in viral shedding. T cell immune responses, believed to be important for the control of HSV-2 infection, increased more than twentyfold to one vaccine antigen (ICP4) and more than tenfold to the other (gD2). In addition, GEN-003 increased neutralizing antibodies to the HSV-2 virus fivefold, on average, compared to baseline values. GEN-003 was well tolerated overall.

Results from an exploratory analysis also suggest that the interval between the first immunization and the next recurrence of genital herpes may be prolonged in patients who received GEN-003 compared to those who received placebo, though this first-in-human clinical trial was not designed to test whether GEN-003 improves symptoms or reduces the frequency of recurrent disease.

"These are the first data that provide compelling evidence that a vaccine administered to people with genital herpes can affect their infection. We are excited that GEN-003 reduced viral shedding as this finding paves the way for future trials that will measure the impact on clinical outbreaks," said Anna Wald, MD, MPH, Principal Investigator of the study and Professor of Medicine, Epidemiology and Laborat
'/>"/>

SOURCE Genocea Biosciences Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
2. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
3. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
4. Omeros Reports Additional Positive Results from OMS824 Program
5. S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poors Factual Stock Reports
6. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
7. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
8. South East Asia Medical Device Market Reports
9. CIVETS Medical Device Market Reports
10. Central Europe and Baltic States Medical Device Market Reports
11. Northen Europe Medical Device Market Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 21, 2014   BioNano Genomics , the ... research centers to purchase an Irys™ System . ... Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and ... obtaining a comprehensive view of a genome was ... does not deliver the scalability or reliability to ...
(Date:10/22/2014)... Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Second quarter overview: , Revenues of $53.9 million, ... Diluted EPS of $0.24, up 33% over last year,s ... revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 ...
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... , , FRANKLIN LAKES, N.J., Jan. 11 ... announced today that it will conduct a live webcast of its ... 2010 at 10:00 a.m. (ET). BD will issue a press ... of the conference call, along with related slides, will be accessible ...
... Calif., Jan. 11 Finesse Solutions, LLC, a manufacturer ... applications, announced the production release of its single-use sensor ... and process temperature, and TruTorr headspace pressure sensors. ... ease of use. It is available on the Thermo ...
Cached Medicine Technology:BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2Single-Use Sensor Product Family Enters High Volume Production 2
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
(Date:10/22/2014)... By Amy Norton ... -- Headlines remain riveted on the three Ebola cases in ... much bigger health threat to Americans. President Barack Obama ... response to the virus, which has infected two Dallas nurses ... this month at Texas Health Presbyterian Hospital. But the ...
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... estimated 15,000 - 20,000,members, ATLANTA, Dec. 4 ... week, to accommodate its growing membership in,DeKalb County ... ceremony for the new Stonecrest Medical Center was ... Ramsey, Georgia State,Representative Stan Watson, DeKalb County Commissioner ...
... The National,Organization of Life & Health Insurance Guaranty ... associations that are playing,a central role in the ... Company of New York (ELNY) matter., NOLHGA ... the ELNY situation: "NOLHGA and all of our ...
... antibiotics and nasal steroids don,t lessen symptoms , , TUESDAY, ... work no better than a placebo in combating sinus ... probably not as effective as have been previously believed, ... said study author Dr. Ian Williamson, a senior lecturer ...
... BMIs experience a significant survival benefit from liver ... transplant compared to patients with normal BMI. Therefore, ... listed for transplantation, say the authors of a ... a journal by John Wiley & Sons. The ...
... and heart,s electrical system , , TUESDAY, Dec. 4 (HealthDay ... spotted patients at highest risk of cardiac arrest or ... researchers report. , "This is important because past studies, ... people at risk," said study lead author Dr. Derek ...
... M.D., Chair of,Neurosurgery at Yale University School of ... American Epilepsy Society (AES), during the,organization,s 61st annual ... physicians and scientists who study and treat epilepsy., ... surgical treatment of,neurological diseases causing epilepsy. He developed ...
Cached Medicine News:Health News:Kaiser Permanente Opens 15th Medical Facility in Georgia 2Health News:Statement on Executive Life of New York Matter 2Health News:Sinusitis Treatments Found Ineffective 2Health News:Sinusitis Treatments Found Ineffective 3Health News:Liver transplant offers survival benefits for patients of all sizes 2Health News:Liver transplant offers survival benefits for patients of all sizes 3Health News:2-in-1 Test Signals Risk After Heart Attack 2Health News:2-in-1 Test Signals Risk After Heart Attack 3
... 20-dione) is a C21 steroid hormone containing ... between C-4 and C-5 (?4).,This steroid hormone ... conjunction with estrogens, regulates,the accessory organs during ... important in preparing the,endometrium for the implantation ...
... The test kit is an enzyme ... format with a liquid phase,incubation, designed ... in serum. The microplate is coated,with ... added to anti-rabbit antibody-coated wells, along ...
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
Medicine Products: